Atossa Genetics (ATOS) Competitors $0.86 -0.02 (-2.76%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$0.90 +0.03 (+3.84%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. CGEM, MBX, RZLT, KMDA, TERN, RGNX, SVRA, TECX, FULC, and SLDBShould you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), Savara (SVRA), Tectonic Therapeutic (TECX), Fulcrum Therapeutics (FULC), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. Atossa Genetics vs. Its Competitors Cullinan Therapeutics MBX Biosciences Rezolute Kamada Terns Pharmaceuticals REGENXBIO Savara Tectonic Therapeutic Fulcrum Therapeutics Solid Biosciences Cullinan Therapeutics (NASDAQ:CGEM) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Which has more risk and volatility, CGEM or ATOS? Cullinan Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Does the media prefer CGEM or ATOS? In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 1 articles in the media. Atossa Genetics' average media sentiment score of 1.89 beat Cullinan Therapeutics' score of 1.87 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Overall Sentiment Cullinan Therapeutics Very Positive Atossa Genetics Very Positive Do institutionals and insiders have more ownership in CGEM or ATOS? 86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 7.2% of Cullinan Therapeutics shares are held by insiders. Comparatively, 7.6% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is CGEM or ATOS more profitable? Cullinan Therapeutics' return on equity of -29.47% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -29.47% -28.19% Atossa Genetics N/A -33.90%-31.53% Do analysts recommend CGEM or ATOS? Cullinan Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 260.14%. Atossa Genetics has a consensus price target of $6.17, suggesting a potential upside of 615.47%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Cullinan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher earnings and valuation, CGEM or ATOS? Atossa Genetics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.86Atossa GeneticsN/AN/A-$25.50M-$0.21-4.10 SummaryAtossa Genetics beats Cullinan Therapeutics on 8 of the 13 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.50M$6.94B$5.73B$9.47BDividend YieldN/A1.28%4.60%3.99%P/E Ratio-4.1025.4327.9319.95Price / SalesN/A49.70438.49101.76Price / CashN/A20.6736.5558.97Price / Book1.514.728.655.90Net Income-$25.50M$176.14M$3.24B$258.42M7 Day Performance2.38%3.35%3.71%2.12%1 Month Performance0.01%3.91%10.34%12.46%1 Year Performance-38.87%8.55%34.54%19.56% Atossa Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics2.3283 of 5 stars$0.86-2.8%$6.17+615.5%-38.4%$114.50MN/A-4.108CGEMCullinan Therapeutics1.4507 of 5 stars$7.87+2.2%$30.00+281.2%-59.0%$464.41MN/A-2.7030Positive NewsMBXMBX Biosciences2.2426 of 5 stars$13.87+6.4%$37.50+170.4%N/A$463.59MN/A0.0036RZLTRezolute2.6388 of 5 stars$5.32+1.1%$11.83+122.4%+26.5%$454.97MN/A-4.6340KMDAKamada3.326 of 5 stars$7.78+0.4%$13.00+67.1%+33.7%$447.39M$167.24M26.83360TERNTerns Pharmaceuticals3.6241 of 5 stars$5.11+4.3%$15.63+205.8%-30.1%$446.31MN/A-4.6940Positive NewsRGNXREGENXBIO4.2711 of 5 stars$8.70+0.2%$31.63+263.5%-33.1%$436.39M$83.33M-2.80370SVRASavara1.9502 of 5 stars$2.51+5.0%$5.60+123.1%-43.5%$433.83MN/A-5.2320Positive NewsTECXTectonic Therapeutic2.634 of 5 stars$23.12+2.1%$83.60+261.6%+31.1%$431.72MN/A-3.16120FULCFulcrum Therapeutics0.6003 of 5 stars$7.90+0.9%$6.29-20.4%-8.6%$426.44M$80M-112.84100Upcoming EarningsSLDBSolid Biosciences3.2936 of 5 stars$5.47+4.0%$15.10+176.1%-24.4%$423.98M$8.09M-1.83100 Related Companies and Tools Related Companies CGEM Alternatives MBX Alternatives RZLT Alternatives KMDA Alternatives TERN Alternatives RGNX Alternatives SVRA Alternatives TECX Alternatives FULC Alternatives SLDB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATOS Stock Alerts